Theravance Biopharma Inc. TBPH
Super Investor & Insider
Nessuna transazione insider negli ultimi 6 mesi.
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Theravance Biopharma is a biopharmaceutical company focused on discovering, developing, and commercializing small-molecule medicines targeting respiratory disease, inflammatory and immunology conditions, and rare disorders. The company's flagship product, YUPELRI (revefenacin), is an FDA-approved once-daily, nebulized …
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees90
TickerTBPH
Statistics
Market Cap$857.5M
Revenue (TTM)$107.5M
Net Income$105.9M
Net Margin98.5%
EPS$2.06
P/E7.39
P/S7.74
P/B2.92
EV/EBITDA74.48
ROE50.2%
Dividend Yield—
Price$16.64
Data: Twelve Data · Revenue = mcap / P/S